Central Nervous System Lymphoma Clinical Trial
Official title:
Selinexor in Combination With Methotrexate and Rituximab for Relapsed /Refractory Central Nervous System (CNS) Lymphoma
This is a single-arm and open-label study to explore X+MTX+Ritu (ATG-010, Methotrexate, Rituximab) regimen in Relapse refractory PCNSL patients. Approximately 30 patients will be enrolled in the study. In dose escalation phase, patients with Relapse refractory PCNSL will be treated with X+MTX+Ritu regimen and escalating doses of oral ATG-010 weekly in a 3+3 design. Then a phase 2 expansion at the recommended dose level based on phase 1b trial will be conducted to evaluate the efficacy, safety and tolerability.
In dose escalation phase, patients with Relapse refractory PCNSL will be treated with X+MTX+Ritu regimen (Methotrexate 3.5 g/m2, d1; Rituximab 375 mg/m2, d0)and escalating doses of oral ATG-010 weekly in a 3+3 design. ATG-010 dose level (DL) 1, 2 and 3 are 60, 80 and 100mg respectively respectively on day 1,8,15,22 for 28-days cycle. The phase 2 expansion at the recommended dose level based on phase 1b trial. The total 6 cycles, 28 days per cycle . And, Subjects participating in the study will undergo a screening period(up to 21days), a treatment period, and a follow-up period. The screening period is a maximum of 21 days before treatment period, And will be followed by 6 cycles of combination treatment(28 days per cycle). partial remission(PR) patients after induction treatment will continue ATG-010 maintenance up to 1 year or until disease progression, intolerable toxicity, death. ;
Status | Clinical Trial | Phase | |
---|---|---|---|
Not yet recruiting |
NCT04516655 -
A Phase II Trail of Chidamide ,Rituximab and Methotrexate in Lymphoma Patients
|
Phase 2 | |
Recruiting |
NCT05054426 -
Intermediate Dose of IV MTX as CNS Prophylaxis for High Risk DLBCL
|
Phase 3 | |
Recruiting |
NCT02623010 -
Bruton's Tyrosine Kinase Inhibitor Ibrutinib as Maintenance Treatment in Elderly Patients With Primary CNS Lymphoma
|
Phase 2 | |
Recruiting |
NCT04548648 -
A Pilot Study of Acalabrutinib in Relapsed/Refractory Primary and Secondary CNS Lymphomas
|
Phase 2 | |
Active, not recruiting |
NCT00293475 -
Methotrexate, Mannitol, Rituximab, and Carboplatin in Treating Patients With Newly Diagnosed Primary Central Nervous System Lymphoma
|
Phase 1/Phase 2 | |
Completed |
NCT03342586 -
Using a Novel Functional MRI Technique to Evaluate for Neurotoxicity
|
||
Terminated |
NCT02420795 -
Akt/ERK Inhibitor ONC201 in Treating Patients With Relapsed or Refractory Non-Hodgkin's Lymphoma
|
Phase 1/Phase 2 | |
Completed |
NCT01011920 -
Trial for Patients With Newly Diagnosed Primary Central Nervous System (CNS) Lymphoma
|
Phase 2 | |
Completed |
NCT00967200 -
Study of Tissue Samples From Patients With Glioma or Other Brain Tumors
|
N/A | |
Recruiting |
NCT03684980 -
LTA Pilot Study of Glucarpidase in Patients With Central Nervous System Lymphoma
|
Early Phase 1 | |
Not yet recruiting |
NCT06213636 -
Fourth-gen CAR T Cells Targeting CD19/CD22 for Highly Resistant B-cell Lymphoma/Leukemia (PMBCL/CNS-BCL).
|
Phase 1/Phase 2 | |
Recruiting |
NCT04938297 -
Rituximab,Zanubrutinib in Combination With Lenalidomide, Followed by Zanubrutinib or Lenalidomide Maintenance in Patients With Primary or Secondary CNS Lymphoma
|
Phase 2 | |
Recruiting |
NCT04792489 -
DALY II USA/ MB-CART2019.1 for DLBCL
|
Phase 2 | |
Completed |
NCT01458730 -
Nordic Study in Newly Diagnosed Primary Central Nervous System (CNS) Lymphoma
|
Phase 2 | |
Completed |
NCT00153530 -
Whole Brain Irradiation in Primary Central Nervous System (CNS) Lymphoma (PCNSL)
|
Phase 4 | |
Recruiting |
NCT04186520 -
CAR-20/19-T Cells in Patients With Relapsed Refractory B Cell Malignancies
|
Phase 1/Phase 2 | |
Recruiting |
NCT05816746 -
Decitabine and Anti-PD-1 in R/R DLBCL
|
Phase 2 | |
Recruiting |
NCT06031194 -
Pharmacogenomics Effects on High-Dose Methotrexate Clearance in Patients With Diffuse Large B-Cell Lymphoma
|
||
Active, not recruiting |
NCT03962127 -
MIDNOR-STROKE- a Long Term Follow-up Study of Patients With First Ever Ischemic Stroke in Central Norway
|
||
Completed |
NCT03690895 -
Long-term Outcome of AIDS-related Primary Central Nervous System Lymphoma Treated With High Dose Methotrexate and Combined Antiretroviral Therapy
|